Pancreatic Cancer Research

ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Wenze Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8200-865X; OpenAlex author ID A5054952702. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Neutrophil extracellular traps induced by tumour-derived NGAL reprogram CAF subtypes via ITGA5 to promote tumour progression in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-337720↗
  2. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejmech.2023.115846↗
  3. Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.003↗
  4. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Co-author DOI 10.1038/s43018-020-00134-z↗
  5. High Cancer Susceptibility Candidate 8 Expression Is Associated With Poor Prognosis of Pancreatic Adenocarcinoma: Validated Analysis Based on Four Cancer Datab… Last author DOI 10.3389/fcell.2020.00392↗
  6. How hsa-miR-495 performed in the tumorigenesis of pancreatic adenocarcinoma by bioinformatics analysis. Last author DOI 10.1002/jcb.28055↗
  7. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0195-y↗
  8. Catechol-O-methyltransferase, a new target for pancreatic cancer therapy. Co-author DOI 10.1111/cas.12648↗
  9. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0116803↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenming Wu · 5 shared papers, 2015–2026 · strength 0.58
  2. Yupei Zhao · 5 shared papers, 2015–2026 · strength 0.58
  3. Xianze Wang · 2 shared papers, 2021–2026 · strength 0.36
  4. Junya Peng · 3 shared papers, 2019–2021 · strength 0.28
  5. W.T. Liu · 1 shared paper, 2026 · strength 0.25
  6. Xudong Liu · 1 shared paper, 2026 · strength 0.25
  7. Aoyi Xiao · 1 shared paper, 2026 · strength 0.25
  8. Renyu Chen · 1 shared paper, 2026 · strength 0.25
  9. Mingyang Liu · 1 shared paper, 2026 · strength 0.25
  10. Yuemei Yang · 2 shared papers, 2019–2020 · strength 0.23
  11. Yu Pei Xiao · 2 shared papers, 2019–2020 · strength 0.23
  12. Hao Chen · 2 shared papers, 2019–2021 · strength 0.18
  13. Yungen Xu · 1 shared paper, 2023 · strength 0.17
  14. Yuepeng Chen · 1 shared paper, 2023 · strength 0.17
  15. Hongmei Dai · 2 shared papers, 2015–2021 · strength 0.16
  16. Yingyi Wang · 1 shared paper, 2020 · strength 0.13
  17. Junliang Lu · 1 shared paper, 2021 · strength 0.11
  18. Huanwen Wu · 2 shared papers, 2015 · strength 0.10
  19. Meilian Zhuo · 1 shared paper, 2021 · strength 0.10
  20. Yong Li · 1 shared paper, 2021 · strength 0.10
  21. Xun Lan · 1 shared paper, 2021 · strength 0.10
  22. Mo Chen · 1 shared paper, 2021 · strength 0.10
  23. Charles J. David · 1 shared paper, 2021 · strength 0.10
  24. Jing Xue · 1 shared paper, 2021 · strength 0.10
  25. Yusheng Chen · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.